Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The Company's lead in-licensed compound, emricasan, is being developed in collaboration with Novartis for the treatment of patients with NASH-driven chronic liver diseases. In addition, Conatus' lead internally developed compound, CTS-2090, is targeting the treatment of patients with chronic diseases involving inflammasome pathways. Source
No articles found.
Rubius Therapeutics developed our proprietary RED PLATFORMÂŽ to generate red blood...
Rubius Therapeutics developed our proprietary R...
As the leader womenâs health, we deliver life-changing and life-saving diagnosti...
As the leader womenâs health, we deliver life...
We are rapidly translating our specific, efficient and versatile CRISPR/Cas9 gene-...
We are rapidly translating our specific, effici...
Celsion Corporation is a fully integrated biopharmaceutical company focused on dev...
Celsion Corporation is a fully integrated bioph...
Nymox Pharmaceutical Corporation specializes in the research and development of th...
Nymox Pharmaceutical Corporation specializes in...
Midatech is an international specialty pharmaceutical company focused on the devel...
Midatech is an international specialty pharmace...
Dicerna is a biopharmaceutical company focused on the discovery and development of...
Dicerna is a biopharmaceutical company focused ...
Join the National Investor Network and get the latest information with your interests in mind.